5 July 2019, Merck Sharp & Dohme (New Zealand) Limited (MSD) today announced that KEYTRUDA® (pembrolizumab) has been registered for the treatment of patients with stage III melanoma (melanoma removed surgically, with cancer found in the lymph nodes). Currently it is registered and funded for patients with advanced or metastatic melanoma.